OptumRx is owned by UnitedHealth Group, Inc. (NYSE: UNH), a publicly traded American healthcare company headquartered in Minnetonka, Minnesota. OptumRx is the pharmacy benefits management segment of Optum, UnitedHealth Group's healthcare services platform. OptumRx processed 1.66 billion adjusted scripts in fiscal year 2025 and generated $154.7 billion in revenues, a 16% increase over 2024. It is one of the three largest pharmacy benefits managers in the United States alongside CVS Caremark and Express Scripts. UnitedHealth Group is led by CEO Stephen Hemsley, who returned to the role in May 2025.
Parent Company
UnitedHealth Group
Founded
2011
Status
Publicly Traded
Headquarters
Minnetonka, Minnesota, USA
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Optum Rx | UnitedHealth Group | Wholly owned |
OptumRx's history begins with UnitedHealth Group's earlier pharmacy services operations, which were consolidated under the OptumRx name when the Optum brand was launched in 2011. UnitedHealth Group had been building pharmacy benefits management capabilities for many years before the OptumRx brand was created.
UnitedHealth Group's pharmacy benefits management operations in the early 2000s were relatively modest compared to the dominant players in the market, CVS Caremark and Medco Health Solutions (later acquired by Express Scripts). The company recognized that pharmacy benefits management was a strategically important capability for a large health insurer, as pharmacy costs represent a significant and growing portion of total healthcare spending.
The Optum brand was formally created in 2011 when UnitedHealth Group consolidated its existing pharmacy and care delivery services under a single unified platform. The pharmacy benefits management business was renamed OptumRx as part of this consolidation.
The most significant event in OptumRx's history was the 2015 acquisition of Catamaran Corporation, a pharmacy benefits management company, for approximately $12.8 billion. Catamaran had been formed through the merger of SXC Health Solutions and Catalyst Health Solutions in 2012 and had grown rapidly to become one of the larger pharmacy benefits managers in the United States. The Catamaran acquisition dramatically expanded OptumRx's scale, making it one of the three largest pharmacy benefits managers in the United States alongside CVS Caremark and Express Scripts.
The Catamaran acquisition brought OptumRx a large book of commercial pharmacy benefits management clients, sophisticated pharmacy technology platforms, and significant mail-order and specialty pharmacy capabilities. The integration of Catamaran's operations into OptumRx was a major undertaking that took several years to complete.
Following the Catamaran acquisition, OptumRx continued to grow both organically and through smaller acquisitions. The business expanded its specialty pharmacy capabilities, which manage high-cost medications for complex conditions such as cancer, autoimmune diseases, and rare diseases. Specialty pharmacy is a high-growth segment of the pharmacy market, as specialty medications represent a growing share of total drug spending.
In 2025, UnitedHealth Group announced that OptumRx would commit to passing through 100% of drug rebates received from pharmaceutical manufacturers to plan sponsors. This policy change represented a significant shift in OptumRx's business model, as pharmacy benefits managers have historically retained a portion of drug rebates as a source of revenue. The announcement reflected increasing regulatory and political pressure on pharmacy benefits managers' rebate practices.
OptumRx's full year 2025 revenues of $154.7 billion represented a 16% increase over 2024, driven by growth in pharmacy services and volume growth from new and existing clients. Earnings from operations were $7.2 billion, compared to $5.8 billion in 2024. Adjusted earnings from operations were $6.1 billion, compared to $5.8 billion a year ago. Adjusted scripts grew to 1.66 billion, up from 1.62 billion in 2024. The increase in earnings was primarily due to growth in both script volume and pharmacy services, as well as operating efficiencies.
In May 2025, CEO Andrew Witty stepped down and Stephen Hemsley returned as CEO. The 2026 outlook projects OptumRx revenues exceeding $150.5 billion, reflecting a planned reduction from 2025 due to membership attrition in UnitedHealthcare. Operating earnings are projected at greater than $6,250 million with an operating margin of approximately 4.2%.
UnitedHealth Group operates through two primary platforms that work together to deliver comprehensive healthcare solutions: UnitedHealthcare and Optum. This integrated business model enables the company to serve the entire healthcare continuum, from insurance coverage to direct healthcare delivery and technology services, creating synergies that enhance both quality and efficiency.
UnitedHealthcare represents the company's health insurance and benefits division, providing coverage to individuals, employers, and government-sponsored programs including Medicare and Medicaid. In 2025, UnitedHealthcare served 49.8 million consumers and achieved revenues of $344.9 billion, representing 16% growth year-over-year. The division operates through multiple business segments including individual and family plans, employer-sponsored coverage, Medicare Advantage plans, and Medicaid managed care programs.
UnitedHealthcare's success stems from its extensive provider networks, innovative benefit designs, and focus on value-based care models. The company has developed sophisticated approaches to care coordination, preventive health programs, and chronic disease management that improve health outcomes while managing costs effectively. UnitedHealthcare's market leadership position enables it to negotiate favorable terms with healthcare providers and develop innovative insurance products that meet evolving consumer needs.
Optum delivers comprehensive healthcare services and technology solutions through three main segments that support the entire healthcare ecosystem:
Optum Health provides direct patient care and health services, operating clinics, surgical centers, and home health services. The segment employs healthcare professionals including physicians, nurses, and care coordinators who deliver integrated care to patients across various settings. Optum Health focuses on value-based care models that align financial incentives with health outcomes, creating more efficient and effective healthcare delivery systems.
Optum Insight offers data analytics, consulting, and technology services to healthcare organizations, payers, and life sciences companies. The segment leverages UnitedHealth Group's vast healthcare data assets to provide insights that improve clinical outcomes, reduce costs, and enhance operational efficiency. Optum Insight's services include population health management, revenue cycle optimization, and healthcare technology implementation.
Optum Rx manages pharmacy benefits for millions of people, negotiating with pharmaceutical manufacturers and managing prescription drug programs. In 2025, Optum Rx achieved 15% revenue growth, demonstrating strong performance in the pharmacy benefits management market. The segment combines purchasing power with clinical expertise to optimize medication therapy, improve adherence, and manage drug costs effectively.
UnitedHealth Group's integrated business model creates significant competitive advantages. The company's ability to combine insurance coverage with direct healthcare delivery enables better care coordination, improved health outcomes, and more efficient resource utilization. This integration also provides valuable data insights that inform product development, care management programs, and operational improvements.
In 2025, UnitedHealth Group demonstrated exceptional financial performance with consolidated revenues of $447.6 billion, representing 12% growth year-over-year. The company's adjusted earnings from operations reached $21.7 billion, reflecting strong operational execution despite challenges including cyberattack-related costs and business restructuring charges.
The company's financial metrics demonstrate operational efficiency and strong cash generation. UnitedHealth Group achieved cash flows from operations of $19.7 billion in 2025, representing 1.5 times net income. The company maintains a debt-to-capital ratio of 43.9% and targets a long-term ratio of 40.0%, reflecting prudent financial management.
UnitedHealth Group employs approximately 440,000 people worldwide, making it one of the largest employers in the healthcare industry. The company's workforce includes healthcare professionals, technology specialists, data analysts, and business professionals who support the company's integrated healthcare delivery model.
Looking toward 2026, UnitedHealth Group has established revenue guidance greater than $439.0 billion and adjusted earnings outlook greater than $17.75 per share. The company expects to continue its growth trajectory while addressing ongoing challenges including medical cost trends, regulatory changes, and competitive pressures in the healthcare market.
OptumRx's sustainability and ethical framework operates within UnitedHealth Group's corporate responsibility programs. As one of the three largest pharmacy benefits managers in the United States, OptumRx's initiatives focus on responsible pharmaceutical services, community pharmacy support, and ethical business practices.
Community Pharmacy Support: In 2025, OptumRx expanded support for independent pharmacies through increased reimbursement for brand drugs. The company increased brand drug reimbursement for approximately 2,300 independent pharmacies, contributing to healthcare access in local communities.
Ethical Pharmacy Benefits Management: In 2025, UnitedHealth Group committed to passing through 100% of drug rebates received from pharmaceutical manufacturers to plan sponsors. This policy change represented a significant shift toward more transparent pricing practices, responding to increasing regulatory and political pressure on PBM rebate practices.
Digital Health and Efficiency: OptumRx's digitally enabled pharmacy services leverage technology to improve service delivery. The company uses technology to help care teams close gaps in care, improving efficiency and reducing the need for physical infrastructure.
Environmental Initiatives: UnitedHealth Group has established environmental sustainability initiatives addressing the health impacts of climate change. OptumRx supports these initiatives through sustainable pharmacy operations and reduced environmental footprint.
OptumRx is recognized as one of the three largest pharmacy benefits managers in the United States, alongside CVS Caremark and Express Scripts. The company processed 1.66 billion adjusted scripts in fiscal year 2025 and generated $154.7 billion in revenues, demonstrating market leadership in the PBM sector.
OptumRx's expanded support for independent pharmacies has been acknowledged as an important initiative for supporting local healthcare infrastructure. The company's commitment to increased reimbursement for 2,300 independent pharmacies has been recognized as contributing to healthcare access in local communities.
OptumRx's innovative approaches to pharmacy benefits management, including the Clear Trend Guarantee and Cost Made Clear payment solutions, have been acknowledged for improving cost transparency for plan sponsors.
OptumRx's strong financial performance in 2025, including 16% revenue growth to $154.7 billion and earnings from operations of $7.2 billion, has been acknowledged as evidence of successful business strategy and market execution.
OptumRx has faced regulatory scrutiny and legal challenges, primarily related to business practices, rebate transparency, and market dominance concerns.
Department of Justice Investigation (2024): OptumRx faced investigation by the Department of Justice regarding business practices, including the prescription management services of OptumRx. This investigation was part of broader scrutiny of UnitedHealth Group's business practices and market dominance in healthcare services.
FTC Action and Response (2024): OptumRx responded to FTC action regarding pharmacy benefits management practices. This regulatory scrutiny reflected increasing attention on pharmacy benefits managers' business practices and market power.
Kentucky Counties Lawsuits: OptumRx invoked the Open Meetings Law to fight Kentucky counties on opioid-related lawsuits, representing a controversial legal strategy. Oldham County's annual budget was less than 0.1% of OptumRx's annual revenue.
Rebate Practice Controversy: OptumRx's traditional practice of retaining drug rebates rather than passing them through to plan sponsors has faced criticism and regulatory pressure. The company's 2025 commitment to passing through 100% of drug rebates represented a significant policy change in response to these concerns.
Market Dominance Concerns: OptumRx's position as one of the three largest PBMs, along with CVS Caremark and Express Scripts, has raised concerns about market concentration and potential anti-competitive practices. The company's market power in pharmacy benefits management has been scrutinized by regulators and policymakers.
Leadership Transition: In May 2025, CEO Andrew Witty stepped down and Stephen Hemsley returned as CEO. The transition occurred amid government investigations, higher than expected medical costs, and public scrutiny following the December 2024 murder of UnitedHealthcare CEO Brian Thompson. UnitedHealth Group also withdrew its 2025 financial outlook at the time of the leadership change.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Cigna | USA | 1986 | Mass market | United states | All-ages | |
| Cvs Health | USA | 1993 | Mass market | United States | All Genders |
Healthcare PharmaceuticalsOwned by The Cigna Group
One of the largest pharmacy benefit managers in the United States, owned by The Cigna Group and operating within its Evernorth Health Services division.
Healthcare PharmaceuticalsOwned by CVS Health
Pharmacy benefit manager owned by CVS Health, administering prescription drug benefits for employers and health plans. In July 2026, Caremark reached a settlement with the FTC over insulin pricing and rebate practices.
Market Positioning: Optum Rx competes with 2 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by UnitedHealth Group, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Unknown Company
Amazon-owned membership-based primary care practice operating nearly 240 offices across more than 20 U.S. markets with 24/7 virtual care.
One Medical operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Pfizer
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
GE HealthCare operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Unknown Company
Leading manufacturer of microscopes and scientific instrumentation for the analysis of microstructures and nanostructures, headquartered in Wetzlar, Germany. A wholly-owned subsidiary of Danaher Corporation, with products including AI-powered imaging software, fluorescence microscopes, and surgical microscopes.
Leica Microsystems operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Koninklijke Philips N.V.
Health technology brand owned by Koninklijke Philips N.V., a publicly traded Dutch company listed on Euronext Amsterdam (PHIA). Covers medical imaging, patient monitoring, and personal health products.
Philips operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Optum Rx which is under a publicly traded parent company.
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
CVS spent $69 billion to buy Aetna. Walgreens acquired Boots for $15 billion. Amazon paid $1 billion for PillPack. Here are 15 pharmacy brands, who owns them, and how a once-diverse industry collapsed into two dominant players.
The supplement industry is worth $60+ billion but most brands are owned by pharma giants and food conglomerates. Here is who owns every major vitamin and supplement brand.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.

Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.